USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ARIDIS PHARMACEUTICALS, LLC
City: SAN JOSE
State: CA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,574,435.00 2
STTR Phase I $543,629.00 1
STTR Phase II $2,922,383.00 1

Award List:

Live, oral, heat Stable S. typhi TY21a vaccine

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eric Patzer
Award Amount: $974,606.00
Abstract:
DESCRIPTION (provided by applicant): Vaccines represent a proven and effective approach for assuring widespread protection of large populations and can be used to reduce the number of susceptible individuals prior to or immediately following a bioterrorism attack. This project addresses two… More

Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: BRIGHAM AND WOMEN'S HOSPITAL
Principal Investigator: Eric J. Patzer
Award Amount: $543,629.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is an autosomal recessive disorder, which leads to the abnormal composition and physical properties of airway secretions in CF patients. Additionally, the lungs of CF patients are particularly susce ptible to chronic bacterial infections with… More

Inhalable Gallium Nitrate Anti-Infective Powder for CF

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: David Lechugaballesteros
Award Amount: $599,829.00
Abstract:
DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is an autosomal recessive disorder, which leads to the abnormal composition and physical properties of airway secretions in CF patients. Additionally, the lungs of CF patients are particularly susce ptible to chronic bacterial infections with… More

Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis

Award Year / Program / Phase: 2011 / STTR / Phase II
Agency: HHS
Research Institution: WAISMAN BIOMANUFACTURING FACILITY, UNIVERSITY OF WISCONSIN
Principal Investigator: Eric J. Patzer – 408-385-1742
Award Amount: $2,922,383.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Over the past two decades, the number of new antimicrobials being developed has experienced a greater than 60% decline, while the number of antibiotic resistant microorganisms has been steadily increasing. Only one newantibacterial drug with a novel mechanism of… More